Navigation Links
Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
Date:10/3/2011

or Contrave; Orexigen's ability to demonstrate that the risk of major adverse CV events in overweight and obese subjects treated with Contrave does not adversely affect the product candidate's benefit-risk profile; the potential for FDA's planned 2012 public advisory committee meeting on obesity drug development to result in additional NDA approval requirements for Contrave as well as post-approval commitments; Orexigen's dependence on Takeda Pharmaceuticals for aspects of the development and commercialization of Contrave; reliance on third parties to supply Contrave and assist with the development of Contrave and the regulatory submissions related thereto; the potential for adverse safety findings relating to Contrave; intense competition in the obesity marketplace and the potential for new products to emerge that provide different or better therapeutic alternatives for obesity and weight loss compared to Contrave; and other risks described in the Company's filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q, which was filed with the SEC on August 8, 2011 and is available from the SEC's website (www.sec.gov) and on our website (www.orexigen.com) under the heading "Investor Relations". All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... NEW YORK , Aug. 1, 2014 ... Square Capital Management, L.P. today responded to the filing ... AGN ) in California.  The complaint makes baseless ... offer rules.  Allergan,s true purpose in ... shareholders, efforts to call a special meeting.  That purpose ...
(Date:8/1/2014)... Aug. 1, 2014 In the latest call ... sexual dysfunction, more than 60 doctors and leading medical ... letter questioning the Food and Drug Administration,s (FDA) decision ... form of male sexual dysfunction compared with ZERO for ... to act for women by approving the first-ever drug ...
(Date:8/1/2014)... Aug. 1, 2014 In the latest call ... sexual dysfunction, more than 60 doctors and leading medical ... letter questioning the Food and Drug Administration,s (FDA) decision ... form of male sexual dysfunction compared with ZERO for ... to act for women by approving the first-ever drug ...
Breaking Medicine Technology:Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 660+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 360+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3
... , CHANGCHUN, China and LOS ... Bulletin Board: CYXN) ("Yongxin" or,"the Company"), a leading pharmaceutical ... the third quarter ended,September 30, 2009. , ... products depend on discretionary,spending, we expect as the economy ...
... , MINNEAPOLIS, Dec. 10 Uroplasty, Inc. ... that develops, manufactures and markets innovative proprietary products to ... the OrBIT Trial of its Urgent® PC Neuromodulation System ... edition of THE JOURNAL OF UROLOGY® . The ...
Cached Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4
(Date:8/1/2014)... News) -- The U.S. Food and Drug Administration announced ... to help fight type 2 diabetes. Jardiance ... treatment regimens to control blood sugar levels in the ... the Office of Drug Evaluation II in the FDA,s ... agency statement. The FDA also recommended that Jardiance ...
(Date:8/1/2014)... 01, 2014 The evolving healthcare ... community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good ... practices and resources to enhance patient care and ... on critical issues to give independent pharmacists the ... , ThoughtSpot show attendance experienced a nearly ...
(Date:8/1/2014)... 01, 2014 Growing prevalence of ... healthcare reforms are boosting healthcare market growth, although ... discounts and increasing generic consumption is a major ... million in 2013, having grown at a Compound ... The implementation of the Health Transformation Program (Saglikta ...
(Date:8/1/2014)... with the progressive, deadly respiratory ailment known as chronic ... battle the disease, the U.S. Food and Drug Administration ... treatment, an inhaled spray called Striverdi Respimat (olodaterol) for ... is often linked to smoking, involves multiple lung conditions ... with COPD may experience a number of symptoms, such ...
(Date:8/1/2014)... Abington, PA (PRWEB) August 01, 2014 ... beneficial than bottle-feeding. A recent study conducted ... may not lag too far behind in terms of ... simply want to know what’s best for their baby. ... , According to Dr. Steven Shapiro , chair ...
Breaking Medicine News(10 mins):Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3
... Flight West (AFW),awarded The Distinguished Pilot award to Oakland ... September 29th. Birely completed,37 Angel Flight West missions over ... in need whose non-emergency health care problems require that,they ... AFW volunteer,pilots, donates the cost of all the missions ...
... and audio web cast on October 9, 2007 --, BELLEVILLE, ON, Oct. 5 /PRNewswire-FirstCall/ - ... Agriculture,(USDA) comment on a field trial for its E. coli O157:H7 cattle vaccine,during a: ... Conference Call & Audio Web Cast ... Tuesday, October 9, 2007 ...
... National Center for Complementary and Alternative Medicine (NCCAM) ... Research on Complementary and Alternative Medicine (CAM) to ... the biological effects of a number of plant-derived ... as dietary supplements, on pancreatic diseases, autoimmune and ...
... oncology tests, SAN DIEGO, Oct. 5 AviaraDx, ... a corporate overview of its molecular,diagnostic test offerings and ... is scheduled for Thursday, November,1st, at 2:30 p.m. in ... Marriott,Del Mar Hotel, 11966 El Camino Real, San Diego, ...
... Texans?, AUSTIN, Texas, Oct. 5 AARP today ... of TXU amounts,to one more backroom deal that ignores ... billion in new debt for a mere,one-time $15 electric ... said Bob Jackson, AARP Texas,state director. "They,ll be the ...
... aren,t consuming recommended levels, experts say , , FRIDAY, Oct. ... officials warned pregnant women to eat no more than ... mercury contamination, many women have been confused, and fish ... says that that warning by the U.S. Food and ...
Cached Medicine News:Health News:Angel Flight West Recognizes Northern California Pilots at AFW 24th Anniversary Awards 2Health News:NCCAM expands Centers of Excellence in CAM research program 2Health News:NCCAM expands Centers of Excellence in CAM research program 3Health News:AARP Calls on State Regulators to Reject Proposed Settlement of TXU Buyout 2Health News:Fish Safe for Pregnant Women to Eat 2Health News:Fish Safe for Pregnant Women to Eat 3
... offers a complete line of flowmeters, available in oxygen, ... available in a variety of calibrations to best suit ... to the gas in use, the Amvex Flowmeter is ... the U with I. For Power Take-Off add PT ...
... Amvex offers a complete line of flowmeters, available in ... all available in a variety of calibrations to best ... specific to the gas in use, the Amvex Flowmeter ... replace the U with I. For Power Take-Off add ...
... complete line of flowmeters, available in oxygen, air, heliox ... a variety of calibrations to best suit your application. ... gas in use, the Amvex Flowmeter is a user ... with I. For Power Take-Off add PT to the ...
0-3.5 LPM Oxygen Flowmeter with Ohmeda male inlet...
Medicine Products: